IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP2004/002850

International Filing Date : 18 March 2004 (18.03.2004)

Priority Date(s) Claimed : 19 March 2003 (19.03.2003)

Applicant(s) (DO/EO/US) : Felix KRATZ, et al.

Title: PROTEIN-BOUND DERIVATIVES OF PLATINUM COMPLEXES CONTAINING CYCLOBUTANE 1,1-DICARBOXYLLATE LIGANDS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

\boxtimes	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this informatio disclosure statement is filed:				
		within three months of the filing date of a national application other than a CPA under § 1.53(d);			
	\boxtimes	within three months of the actual filing date of the national phase of a PCT application; OR			
		before the mailing of a first substantive office action (including after filing of an RCE).			
		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods led in 37 C.F.R. § 1.97(b), but before the mailing date of:			
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and			



69/549311

is accompanied by: JC05 Rec'd PCT/PTO 1 6 SEP 2005

			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR		
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).		
		ler 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the met of the following actions which have not been withdrawn:			
		a final	action under 37 C.F.R. § 1.113;		
		termina	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);		
		OR a n	notice of allowance under 37 C.F.R. § 1.311;		
	AND i	is filed o	on or before payment of the issue fee; AND is accompanied by:		
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 0 under 37 C.F.R. § 1.17(p).		
Staten	nents Ur	nder 37	C.F.R. 1.97(e)		
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or		
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.		
Cited	Materia	<u>ls</u>			
		Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).			
	\boxtimes	•	s of materials listed but not attached were cited in an international search dated <u>July 9, 2004</u> .		
		Not rec	quired by 37 CFR § 1.98.		
		Copies	s of the materials listed are attached (except for the foregoing).		

JC05 Rec'd PCT/PTO 1 6 SEP 2005

OU/549311

Non-English Language References

\boxtimes	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document
	A = document defining the general state of the art O = non-written disclosure
	P = intercalated document T = document cited to understand the theory or principle underlying the invention
	E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
	D = cited in the application L = cited for another reason
	& = publication of member of same patent family
	Translation of other relevant information on foreign search report
Other Info	ormation_
Payment of	of Fees Due (If Any):
A	check for \$ covering the fee identified above is attached.
☐ Pl	ease charge to Deposit Account No. 13-3402 \$ for the fee identified above.





The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969 Attorney/Agent for Applicants


MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza l 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: WEICKM-0049

Date: September 16, 2005

AJZ:ssr



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number USNP of BCT/EP2004/002850 INFORMATION DISCLOSURE 18 March 40 Filing Date Felix KRATZ, et al STATEMENT BY APPLICANT First Named Inventor **Group Art Unit** unknown (use as many sheets as necessary) **Examiner Name** unknown WEICKM-0049 Sheet of Attorney Docket Number

	U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No.1		Kind Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
	001	5,011,959		KHOKHAR, ABDUL R.	04-30-1991			
					1			
	1 1							

FOREIGN PATENT DOCUMENTS								
		Foreign Patent Document			Pages, Columns, Lines, Date of Publication of Where Relevant			
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Т*

Examiner Signature	 Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.





PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known L. F. A. USNP of PCT/EP2004/002850 Substitute for form 1449A/PTO **Application Number** INFORMATION DISCLOSURE Filing Date 18 March 2004 (18.03.2004) STATEMENT BY APPLICANT Felix KRATZ, et al. First Named Inventor Group Art Unit unknown (use as many sheets as necessary) **Examiner Name** unknown Sheet 2 of Attorney Docket Number WEICKM-0049

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	002	PASHKOVSKII F.S., KHLEBNIKOVA T.S., LAKHVICH F.A.: "GENERAL APPROACH TO SYNTHESIS OF CARBOPLATIN ANALOG CONTAINING FRAGMENTS OF CARBOXYLIC FATTY ACIDS IN ACID LIGAND" BELARUSKAYA NAVUKA, vol. 46, no. 4, 2002, pages 63-65			
		BOECKLER C ET AL: "IMMUNOGENICITY OF NEW HETEROBIFUNCTIONAL CROSS-LINKING REAGENTS USED IN THE CONJUGATION OF SYNTHETIC PEPTIDES TO LIPOSOMES" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 191, no. 1, 10 May 1996, pages 1-10			
	004	LEBWOHL D ET AL: "CLINICAL DEVELOPMENT OF PLATINUM COMPLEXES IN CANCER THERAPY: AN HISTORICAL PERSPECTIVE AND AN UPDATE" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 34, no. 10, September 1998, pages 1522-1534			
		·			
	<u> </u>				
	ł				

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.